The Indian Pharmacopoeia Commission (IPC), an autonomous institution under the Ministry of Health and Family Welfare, Government of India, organized a National Conference on “Ensuring Quality of Blood and Blood Components through IP 2026” at its campus in Ghaziabad on June 24, 2026, to facilitate awareness and implementation of the newly introduced blood and blood component monographs in the Indian Pharmacopoeia (IP) 2026.

The conference brought together over 160 participants, including blood centre professionals, quality assurance and quality control officers, State Licensing Authorities, haemovigilance experts, and government health officials from Uttar Pradesh, Rajasthan, Uttarakhand, Haryana, Punjab, and Madhya Pradesh.

The inaugural session was addressed by Harsh Mangla, Joint Secretary (Drug and Food Regulation), Department of Health and Family Welfare, Government of India, virtually. He appreciated IPC's efforts in introducing pharmacopoeial standards for blood and blood components in IP 2026 (exclusively), not present in any other pharmacopoeia. 

Dr. G. N. Singh, Advisor to the Chief Minister of Uttar Pradesh and Former Secretary-cum-Scientific Director, IPC, also graced the inaugural session. The programme commenced with a welcome address by Dr. Jai Prakash, Senior Principal Scientific Officer, IPC, followed by introductory remarks from Dr. V. Kalaiselvan, Secretary-cum-Scientific Director, IPC.

Addressing the participants, Dr. V. Kalaiselvan highlighted the significance of the newly incorporated standards for blood and blood components in IP 2026, emphasizing their role in strengthening quality assurance, patient safety, and regulatory compliance in transfusion services. 

The conference featured technical sessions on IP 2026 standards for blood and blood components, regulatory requirements, rational use of blood, plasma quality, the National Formulary of India (NFI), the Haemovigilance Programme of India (HvPI), and IP Online. 

A panel discussion involving experts from IPC, State Licensing Authorities, HvPI, and transfusion medicine institutions deliberated on implementation strategies and emerging regulatory expectations.

The conference served as a platform for stakeholder engagement and capacity building, enabling blood centres to prepare for the effective adoption of IP 2026 standards. 

Participants reaffirmed their commitment to implementing the updated standards to further enhance the quality, safety, and efficacy of blood and blood components across the country.